Preservation of Tetherin and CD4 Counter-Activities in Circulating Vpu Alleles despite Extensive Sequence Variation within HIV-1 Infected Individuals

PLoS Pathogens

Volumn 10, Issue 1, 2014, Pages

  Pickering, Suzanne ^a   Hué, Stephane ^b   Kim, Eun Young ^c   Reddy, Susheel ^c   Wolinsky, Steven M ^c   Neil, Stuart J D ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BST2 PROTEIN, HUMAN; CD4 ANTIGEN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOCYTE ANTIGEN; VIRUS PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ALLELE; CLINICAL TRIAL; COMPARATIVE STUDY; DOWN REGULATION; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENETICS; HEK293 CELL LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE;

ALLELES; ANTIGENS, CD; ANTIGENS, CD4; DOWN-REGULATION; FEMALE; FOLLOW-UP STUDIES; GENETIC VARIATION; GPI-LINKED PROTEINS; HEK293 CELLS; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MALE; NF-KAPPA B; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 84893715654     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003895     Document Type: Article

References (68)

1. Malim MH, Emerman M, (2008) HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3: 388-398.
2. Li Y, Ndjango JB, Learn GH, Ramirez MA, Keele BF, et al. (2012) Eastern chimpanzees, but not bonobos, represent a simian immunodeficiency virus reservoir. J Virol 86: 10776-10791.
3. Sauter D, Schindler M, Specht A, Landford WN, Munch J, et al. (2009) Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6: 409-421.
4. Dube M, Bego MG, Paquay C, Cohen EA, (2010) Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology 7: 114.
5. Le Tortorec A, Willey S, Neil SJ, (2011) Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction. Viruses 3: 520-540.
6. Cocka LJ, Bates P, (2012) Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog 8: e1002931.
7. Galao RP, Le Tortorec A, Pickering S, Kueck T, Neil SJ, (2012) Innate sensing of HIV-1 assembly by Tetherin induces NFkappaB-dependent proinflammatory responses. Cell Host Microbe 12: 633-644.
8. Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R, et al. (2013) Stimulation of NF-kappaB Activity by the HIV Restriction Factor BST2. J Virol 87: 2046-2057.
9. Shah AH, Sowrirajan B, Davis ZB, Ward JP, Campbell EM, et al. (2010) Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe 8: 397-409.
10. Matusali G, Potesta M, Santoni A, Cerboni C, Doria M, (2012) The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR. J Virol 86: 4496-4504.
11. Moll M, Andersson SK, Smed-Sorensen A, Sandberg JK, (2010) Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. Blood 116: 1876-1884.
12. Alter G, Heckerman D, Schneidewind A, Fadda L, Kadie CM, et al. (2011) HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 476: 96-100.
13. Sauter D, Unterweger D, Vogl M, Usmani SM, Heigele A, et al. (2012) Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein. PLoS Pathog 8: e1003093.
14. Vigan R, Neil SJ, (2011) Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. J Virol 85: 9737-9748.
15. Sauter D, Hue S, Petit SJ, Plantier JC, Towers GJ, et al. (2011) HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef. Retrovirology 8: 103.
16. Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM, (2011) Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology 8: 78.
17. Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, et al. (2010) Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 7: 13.
18. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, et al. (2009) Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 5: e1000429.
19. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, et al. (2009) Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6: 54-67.
20. Le Tortorec A, Neil SJ, (2009) Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 83: 11966-11978.
21. Douglas JL, Bai Y, Gustin JK, Moses AV, (2013) A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress. Virology 441: 182-196.
22. Verma S, Ronsard L, Kapoor R, Banerjea AC, (2013) Genetic characterization of natural variants of Vpu from HIV-1 infected individuals from Northern India and their impact on virus release and cell death. PLoS One 8: e59283.
23. Liberatore RA, Bieniasz PD, (2011) Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci U S A 108: 18097-18101.
24. Barrett BS, Smith DS, Li SX, Guo K, Hasenkrug KJ, et al. (2012) A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo. PLoS Pathog 8: e1002596.
25. Jones PH, Mehta HV, Maric M, Roller RJ, Okeoma CM, (2012) Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo. Retrovirology 9: 10.
26. Casartelli N, Sourisseau M, Feldmann J, Guivel-Benhassine F, Mallet A, et al. (2010) Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog 6: e1000955.
27. Jolly C, Booth NJ, Neil SJ, (2010) Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol 84: 12185-12199.
28. Zhong P, Agosto LM, Ilinskaya A, Dorjbal B, Truong R, et al. (2013) Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. PLoS One 8: e53138.
29. Strebel K, Klimkait T, Maldarelli F, Martin MA, (1989) Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol 63: 3784-3791.
30. Homann S, Smith D, Little S, Richman D, Guatelli J, (2011) Upregulation of BST-2/Tetherin by HIV infection in vivo. J Virol 85: 10659-10668.
31. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, et al. (2012) Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A 109: 3035-3040.
32. Mikhail M, Wang B, Saksena NK, (2003) Mechanisms involved in non-progressive HIV disease. AIDS Rev 5: 230-244.
33. Anzala OA, Nagelkerke NJ, Bwayo JJ, Holton D, Moses S, et al. (1995) Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis 171: 686-689.
34. Poropatich K, Sullivan DJ Jr, (2011) Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. J Gen Virol 92: 247-268.
35. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557.
36. Vigan R, Neil SJ, (2010) Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol 84: 12958-12970.
37. Kueck T, Neil SJ, (2012) A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. PLoS Pathog 8: e1002609.
38. Magadan JG, Bonifacino JS, (2012) Transmembrane domain determinants of CD4 Downregulation by HIV-1 Vpu. J Virol 86: 757-772.
39. Margottin F, Bour SP, Durand H, Selig L, Benichou S, et al. (1998) A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1: 565-574.
40. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, et al. (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3: 245-252.
41. McNatt MW, Zang T, Bieniasz PD, (2013) Vpu binds directly to tetherin and displaces it from nascent virions. PLoS Pathog 9: e1003299.
42. Bour S, Perrin C, Akari H, Strebel K, (2001) The human immunodeficiency virus type 1 Vpu protein inhibits NF-kappa B activation by interfering with beta TrCP-mediated degradation of Ikappa B. J Biol Chem 276: 15920-15928.
43. Besnard-Guerin C, Belaidouni N, Lassot I, Segeral E, Jobart A, et al. (2004) HIV-1 Vpu sequesters beta-transducin repeat-containing protein (betaTrCP) in the cytoplasm and provokes the accumulation of beta-catenin and other SCFbetaTrCP substrates. J Biol Chem 279: 788-795.
44. Alizon S, Fraser C, (2013) Within-host and between-host evolutionary rates across the HIV-1 genome. Retrovirology 10: 49.
45. Serra-Moreno R, Jia B, Breed M, Alvarez X, Evans DT, (2011) Compensatory Changes in the Cytoplasmic Tail of gp41 Confer Resistance to Tetherin/BST-2 in a Pathogenic Nef-Deleted SIV. Cell Host Microbe 9: 46-57.
46. Gotz N, Sauter D, Usmani SM, Fritz JV, Goffinet C, et al. (2012) Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. Cell Host Microbe 12: 373-380.
47. Loschko J, Schlitzer A, Dudziak D, Drexler I, Sandholzer N, et al. (2011) Antigen delivery to plasmacytoid dendritic cells via BST2 induces protective T cell-mediated immunity. J Immunol 186: 6718-6725.
48. Hotter D, Kirchhoff F, Sauter D, (2013) HIV-1 Vpu does not degrade interferon regulatory factor 3. J Virol 87: 7160-7165.
49. Karin M.S. L.M., editor (2010) NF-kappaB: A Network Hub Controlling Immunity, Inflammation, and Cancer: CSH Press.
50. Lucas TM, Janaka SK, Stephens EB, Johnson MC, (2012) Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail. PLoS One 7: e51741.
51. Schmidt S, Fritz JV, Bitzegeio J, Fackler OT, Keppler OT, (2011) HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. MBio 2: e00036-00011.
52. Mauxion F, Le Borgne R, Munier-Lehmann H, Hoflack B, (1996) A casein kinase II phosphorylation site in the cytoplasmic domain of the cation-dependent mannose 6-phosphate receptor determines the high affinity interaction of the AP-1 Golgi assembly proteins with membranes. J Biol Chem 271: 2171-2178.
53. Hill MS, Ruiz A, Schmitt K, Stephens EB, (2010) Identification of amino acids within the second alpha helical domain of the human immunodeficiency virus type 1 Vpu that are critical for preventing CD4 cell surface expression. Virology 397: 104-112.
54. Singh SK, Mockel L, Thiagarajan-Rosenkranz P, Wittlich M, Willbold D, et al. (2012) Mapping the interaction between the cytoplasmic domains of HIV-1 viral protein U and human CD4 with NMR spectroscopy. FEBS J 279: 3705-3714.
55. Tiganos E, Yao XJ, Friborg J, Daniel N, Cohen EA, (1997) Putative alpha-helical structures in the human immunodeficiency virus type 1 Vpu protein and CD4 are involved in binding and degradation of the CD4 molecule. J Virol 71: 4452-4460.
56. Schubert U, Strebel K, (1994) Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol 68: 2260-2271.
57. Sato K, Misawa N, Fukuhara M, Iwami S, An DS, et al. (2012) Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice. J Virol 86: 5000-5013.
58. Dave VP, Hajjar F, Dieng MM, Haddad E, Cohen EA, (2013) Efficient BST2 antagonism by Vpu is critical for early HIV-1 dissemination in humanized mice. Retrovirology 10: 128.
59. Hatziioannou T, Evans DT, (2012) Animal models for HIV/AIDS research. Nat Rev Microbiol 10: 852-867.
60. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43: 406-413.
61. Rambaut A (2002) Se-Al, version 2.0a11. Available: http://treebioedacuk/software/seal/ Accessed August 2013.
62. Silvestro D, Michalack I, (2012) raxmlGUI: a graphical front-end for RAxML. Organisms Diversity & Evolution 12: 335-337.
63. Rambaut A (2006) Figtree, version 1.3.1. Available: http://treebioedacuk/software/figtree/ Accessed August 2013.
64. Pond SL, Frost SD, Muse SV, (2005) HyPhy: hypothesis testing using phylogenies. Bioinformatics 21: 676-679.
65. Delport W, Poon AF, Frost SD, Kosakovsky Pond SL, (2010) Datamonkey 2010: a suite of phylogenetic analysis tools for evolutionary biology. Bioinformatics 26: 2455-2457.
66. Nguyen KL, Llano M, Akari H, Miyagi E, Poeschla EM, et al. (2004) Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 319: 163-175.
67. Miyagi E, Andrew AJ, Kao S, Strebel K, (2009) Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A 106: 2868-2873.
68. Niranjanakumari S, Lasda E, Brazas R, Garcia-Blanco MA, (2002) Reversible cross-linking combined with immunoprecipitation to study RNA-protein interactions in vivo. Methods 26: 182-190.